Strategic Expansion ProCure is an established proton therapy center with a track record of treating over 7,000 patients since opening in 2012, indicating ongoing capacity for partnerships, referrals, and regional expansion opportunities within the NJ/NY tri-state area.

Advanced Technology The center utilizes Pencil Beam Scanning (PBS), the most advanced proton therapy technology, suggesting potential for collaboration with pharma, clinical research groups, and device manufacturers seeking centers with cutting-edge capabilities.

Patient-Centric Diff ProCure emphasizes non-surgical, targeted treatments with fewer side effects and downtime, which can be leveraged in value-based sales discussions with payers, employers, and patient advocacy groups seeking high-quality, life‑impactful cancer care.

Geographic Reach Located in Somerset, NJ, and as the first proton center in the NJ/NY tri-state region, there is potential for regional affinity partnerships, referrals, and joint marketing with nearby healthcare networks and academic partners.

Growth Readiness With a modest staff size (51-200 employees) and a revenue range of 10–25 million, ProCure appears scalable for managed service partnerships, equipment maintenance contracts, and technology integrations that support operational efficiency and patient access.